Immunology & Inflammatory Diseases
Bringing together scientific insight, operational agility, and digital oversight to advance immunology research with confidence.
Immunology & Inflammatory Diseases
Bringing together scientific insight, operational agility, and digital oversight to advance immunology research with confidence.
Complexity Made Manageable: Precision in Immune-Driven Studies
Where variability is high, our operational clarity stays constant.
Immunology and inflammatory studies often involve unpredictable disease activity, fluctuating biomarkers, and multi-system complexity. At UNIQ, we build trial frameworks that remain stable even when conditions change.
Our teams specialize in autoimmune disorders, dermatologic inflammation, respiratory immune conditions, and systemic rare immunologic diseases. We leverage adaptive visit schedules, biomarker-guided endpoints, and symptom-tracking technologies to reduce variability and capture high-fidelity data.
With proactive risk modeling and real-time oversight, we identify deviations early and maintain consistency across regions, sites, and patient cohorts.
Global Immunology Site Network & Specialized Patient Cohorts
Connecting your study to the right expertise, the right patients, and the right data.
Immunology and inflammatory disorders require sites with highly specialized diagnostic capabilities, experienced investigators, and consistent access to well-defined patient cohorts.
At UNIQ, our global network includes leading centers in rheumatology, dermatology, gastroenterology, pulmonology, and allergy/immunology, giving sponsors a direct path to faster enrollment and higher study predictability.
We support you from the earliest planning stages – including feasibility assessments, site intelligence, and cohort profiling to ensure each study is placed exactly where it can succeed. Our teams evaluate disease prevalence, historical site performance, biomarker testing capability, and access to treatment-naïve or phenotype-specific populations.
- 38% faster enrollment at pre-qualified immunology centers
- 87% screening-to-randomization success rate in immune-mediated trials
- 30+ countries activated for immunology & inflammatory studies
- 95% investigator satisfaction with our operational support